Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR3 | Q9UBY5 | 7/20 | 0.37 |
| ▸ | LPAR2 | Q9HBW0 | 5/20 | 0.37 |
| ▸ | LPAR1 | Q92633 | 4/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | FDPS | P14324 | 1/20 | 0.36 |
| ▸ | MVD | P53602 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15780668 | 0.98 | FDPS (0.39) | LPAR3LPAR2LPAR1ACHEFDPS | |
| SCHEMBL14048919 | 0.96 | FDPS (0.42) | LPAR3LPAR2LPAR1ACHEFDPS | |
| SCHEMBL14048820 | 0.94 | LPAR3 (0.38) | LPAR3LPAR2LPAR1ACHEMVD | |
| SCHEMBL15780665 | 0.77 | MVD (0.40) | LPAR3LPAR2LPAR1MVD | |
| SCHEMBL8154759 | 0.77 | ACHE (0.34) | ACHEFDPS | |
| SCHEMBL8154491 | 0.76 | ACHE (0.36) | ACHEFDPS | |
| SCHEMBL10241835 | 0.76 | LPAR3 (0.37) | LPAR3LPAR2LPAR1FDPS | |
| SCHEMBL8639035 | 0.76 | ACHE (0.36) | ACHEFDPS | |
| SCHEMBL3436790 | 0.76 | PIK3CD (0.37) | ACHE | |
| SCHEMBL3429744 | 0.75 | LPAR3 (0.32) | LPAR3LPAR2LPAR1FDPSMVD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9018191-B2 | Phosphonoxy quinazoline derivatives and their pharmaceutical use | ASTRAZENECA AB (SE) | 2015-04-28 | — | — | US | disclosed |
| US-20140162984-A1 | PHOSPHONOXY QUINAZOLINE DERIVATIVES AND THEIR PHARMACEUTICAL USE | ASTRAZENECA AB (SE) | 2014-06-12 | — | — | US | disclosed |
| EP-1575966-B1 | THERAPEUTIC QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2008-10-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140162984-A1 | PHOSPHONOXY QUINAZOLINE DERIVATIVES AND THEIR PHARMACEUTICAL USE | PLK2, ABL1, CYP3A5 | LPAR3 3136/4885LPAR2 3649/4885LPAR1 3601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.